Completed Phase 1 and Phase 2 studies show good efficacy and safety of BupiZenge®. In Phase 2 it was shown *:
- that BupiZenge® reduced pain in the mouth by 50% compared to standard treatment (p = 0.0002).
- in the combined effect variable, pain in the mouth and throat, the pain decreased by 31% (p = 0.0032)
- few and mild side effects, no serious adverse events
*See under publications, Pain reports 2017
More about our Publications here